Biomarker Discovery for Peptide Therapeutics: Patient Stratification, Treatment Response, and 2026 Precision Medicine

Industry Authority | 2026-07-10 | 12 min read

A 2026 industry guide to biomarker discovery for peptide therapeutics: pharmacodynamic biomarkers, predictive biomarkers, companion diagnostics, and precision medicine applications.

Introduction: biomarkers as the foundation of precision medicine

Biomarkers are measurable indicators of biological processes, disease states, or therapeutic responses. In peptide drug development, biomarkers enable:

• Patient stratification
• Treatment response monitoring
• Dose optimization
• Mechanism confirmation
• Companion diagnostics

This 2026 guide covers biomarker discovery and applications for peptide therapeutics.

Biomarker classification

Diagnostic biomarkers

Diagnostic biomarkers identify disease presence:

• Glucose and HbA1c for diabetes
• NAFLD/MASH fibrosis scores (FIB-4, NFS)
• Genetic markers for rare diseases

Pharmacodynamic (PD) biomarkers

PD biomarkers demonstrate target engagement:

• GLP-1 receptor agonists: GLP-1 levels, GIP levels, glucagon levels
• GHRH analogs: IGF-1 levels, GH levels
• Thymosin alpha-1: immune cell markers

Predictive biomarkers

Predictive biomarkers predict treatment response:

• Responders vs. non-responders
• Optimal dose for individual patients
• Risk of adverse events

Monitoring biomarkers

Monitoring biomarkers track disease progression:

• Weight for obesity
• HbA1c for diabetes
• ALT/AST for liver disease
• Fibroscan for MASH

Prognostic biomarkers

Prognostic biomarkers predict disease outcome:

• Fibrosis stage for MASH
• Baseline HbA1c for diabetes
• Tumor markers for cancer

Biomarkers for metabolic peptides

GLP-1 receptor agonists

| Biomarker | Relevance | Measurement | | --- | --- | --- | | Fasting glucose | Glycemic control | Fingerstick or lab | | HbA1c | Long-term glycemic | HPLC or immunoassay | | Body weight | Weight loss efficacy | Scale | | GLP-1 levels | Target engagement | ELISA or LC-MS | | GIP levels | Dual agonist mechanism | ELISA | | Glucagon | Metabolic effects | RIA or ELISA | | C-peptide | Insulin secretion | Immunoassay | | Lipids (LDL, HDL, TG) | Cardiovascular risk | Lab panel |

GLP-1/GIP dual agonists

| Biomarker | Relevance | | --- | --- | | GIP levels | Dual mechanism | | Metabolic rate | Energy expenditure | | Liver fat | MASH/NASH effects | | Appetite scores | Patient-reported outcomes |

Growth hormone peptides

| Biomarker | Relevance | | --- | --- | | IGF-1 | GH target engagement | | IGFBP-3 | GH effect | | GH levels | Direct measurement | | Body composition | DEXA for muscle/fat |

Biomarker discovery workflow

Stage 1: Hypothesis generation

Begin with mechanistic understanding:

• What is the drug's mechanism?
• What biological pathways are affected?
• What measurable changes would indicate target engagement?

Stage 2: Assay development

Develop assays for candidate biomarkers:

• Immunoassays (ELISA, MSD, Simoa)
• LC-MS/MS for small molecules
• Genomic assays (qPCR, RNA-seq)
• Cellular assays (flow cytometry)

Stage 3: Clinical validation

Validate biomarkers in clinical samples:

• Correlation with efficacy endpoints
• Sensitivity and specificity
• Reproducibility across labs
• Clinical utility

Stage 4: Regulatory qualification

Regulatory qualification establishes clinical utility:

• FDA Biomarker Qualification Program
• EMA Qualification of Novel Methodologies
• CDRH biomarker review

Companion diagnostics

What is a companion diagnostic?

A companion diagnostic (CDx) is a test that:

• Identifies patients likely to benefit from therapy
• Identifies patients at risk of adverse events
• Guides treatment decisions

For peptide therapeutics, companion diagnostics are emerging for:

• Rare disease peptides (genetic mutations)
• Oncology peptides (tumor markers)
• Personalized medicine (patient-specific)

CDx development pathway

• Identify biomarker linked to treatment response
• Develop diagnostic assay (IVD)
• Validate assay performance (sensitivity, specificity)
• Establish clinical validity
• Co-develop with drug (parallel filing)
• FDA/EMA approval as IVD

Examples of peptide companion diagnostics

| Peptide | Companion Diagnostic | | --- | --- | | Metreleptin | Leptin levels, genetic testing for lipodystrophy | | Teduglutide | Short bowel syndrome markers | | Growth hormone | IGF-1 levels, GH stimulation tests | | Thymosin alpha-1 | Immune cell profiling |

Biomarkers for patient stratification

Enrichment strategies

Patient enrichment increases trial success:

• Select patients most likely to respond
• Reduce sample size and cost
• Increase signal-to-noise ratio

Example: Select patients with MASH F2-F3 fibrosis for MASH trials (vs. all NAFLD patients).

Subgroup identification

Biomarkers identify subgroups with different responses:

• Weight loss responders vs. non-responders
• Glycemic responders vs. non-responders
• Patients requiring dose escalation

Real-world evidence integration

RWE (real-world evidence) biomarkers:

• Electronic health records (EHR)
• Claims databases
• Patient registries
• Wearable device data

Emerging biomarker technologies

Multi-omics approaches

| Technology | Application | | --- | --- | | Genomics | Genetic variants affecting drug response | | Transcriptomics | Gene expression changes | | Proteomics | Circulating protein biomarkers | | Metabolomics | Metabolic pathway effects | | Lipidomics | Lipid mediator changes |

Liquid biopsies

Non-invasive biomarker detection:

• Circulating tumor DNA (ctDNA)
• Exosomes
• Circulating peptides (LC-MS)
• MicroRNAs

Artificial intelligence

AI/ML for biomarker discovery:

• Pattern recognition in multi-omics data
• Predictive modeling for treatment response
• Patient clustering for stratification

Regulatory considerations

FDA biomarker qualification

FDA's Biomarker Qualification Program provides:

• Pathway for biomarker validation
• Regulatory acceptance for drug development
• Public-private partnerships (C-Path)

Labeling implications

Biomarker-driven labeling:

• Companion diagnostic requirements
• Subgroup-specific dosing
• Contraindications for biomarker-negative patients

Summary

Biomarkers are essential tools for peptide drug development. They enable patient stratification, treatment response monitoring, mechanism confirmation, and precision medicine approaches. Companion diagnostics are emerging for peptide therapeutics, enabling personalized treatment strategies.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.